Challenges in the Detection of Metabolic Biomarkers Using a Multi Plex Assay

02/12/2021

A 5 Plex method for the detection of metabolic biomarkers in human plasma was developed using the U-PLEX technology on the MSD platform.

The complexities surrounding this method were the establishment of endogenous QCs for each chosen biomarker and evaluating the potential use and need for buffer QCs vs matrix QCs where applicable. Additional challenges were faced while trying to ascertain a single minimum required dilution to enable accurate quantification of all biomarkers simultaneously, encompassing the different detection ranges and limits for each biomarker.

READ MORE

Considerations to properly assess drug stability within biological samples

Assessing drug stability during method development and validation is of paramount importance. The concentration of the target analyte must remain unaffected throughout the lifecycle of the samples to ensure the reliability of the assay data. However, a decrease in analyte concentration in a biological fluid is not always due to a lack of stability.

READ MORE

Challenges in development of robust analytical methods for the quantitation of low molecular weight compounds by LC-MS/MS

14/06/2021

Method development can be considered one of the most challenging task in a Bioanalytical laboratory. When working with LC-MS/MS and low molecular weight drugs, low degree of ionization, poor fragmentation, higher presence of isobaric compounds or analyte loss due to their high volatility can get in the way of a successful method development.

READ MORE

Qualification of a method for the measurement of a potentially therapeutic protein

04/06/2021

A recent project completed by Anapharm involved qualifying an analytical method for the measurement of a therapeutic protein in human skin tissue. The protein of interest is one that is expressed ubiquitously in a number of tissues and cell types.

READ MORE

Successful WHO Inspection

30/10/2020

Anapharm Bioanalytics is proud to announce that it has successfully undergone World Health Organization GCP/GLP compliance inspection at its Barcelona based bioanalytical lab

READ MORE

Cell Lab | Anapharm Bioanalytics expands its laboratory capabilities

08/05/2020

We are glad to inform you that a cell lab has recently been built at our facilities in Barcelona. Our brand new cell lab capabilities will enable the development and validation of a variety of assays such as Cell Proliferation, Ligand Stimulated Cell Signalling, Protein Secretion, Reporter Gene, NAbs, etc.

READ MORE

Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal

31/03/2020

Anapharm Bioanalytics is proud to announce that it has recently (February 20th, 2020) renewed its ANVISA (Brazil) certificate. The renewed certification is valid until February 20th, 2022.

READ MORE

Anapharm Bioanalytics Receives Certification for French Research Tax Credit

27/01/2020

Anapharm Bioanalytics is pleased to announce it has renewed its French research Tax Credit certification (Crédit d’Impôt Recherche) for period 2020 – 2024.

READ MORE

Anapharm Bioanalytics’ successful FDA Inspection

12/06/2019

Anapharm Bioanalytics is proud to announce that it has successfully undergone another US FDA inspection at its Barcelona based bioanalytical lab. The inspection, that took place in June 2019, had a focus on a total of 8 studies. This was the second unannounced FDA inspection at our facilities without any observations; no 483 form issued.

READ MORE